DeepLook, Inc.’s Segmentation and Measurement Tool Captures FDA Clearance
One-click tool is designed to deliver precision consistently across all imaging modalities.
Connecticut-based software firm DeepLook, Inc., announced Thursday it has received U.S. Food & Drug Administration approval for DL Precise, its one-click segmentation and measurement tool.
This tool is designed to automate segmentation and measurement of suspicious findings across all imaging modalities, potentially improving workflow and reporting precision. Still, company officials noted, users can maintain full control and modify any automated measurement if they choose.
At left, one-click segmentation and measurement rendered by DL Precise. At right, DL Precise uses vivid color to illustrate segmentation.
Credit: DeepLook
DL Precise uses deterministic algorithms to contour object margins and measure long and short dimension axes, area, and estimated volume. With its single-click activation, it side-steps the complex, time-consuming manual set-up that frequently comes with current semi-automatic segmentation tools.
Not only does DL Precise work with any DICOM image and on all 510(k)-cleared viewers, but its patented technology can also be used universally with mammography, ultrasound, CT, and MRI, and the data captured can be fed directly into structured reports, making image comparisons across modalities easier. It can also be adapted to each viewer interface for easy PACS integration, according to company data.
DeepLook also has plans for future decision-support and diagnostic products based on radiomic data.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.
Can a Six-Minute MRI Facilitate Detection of Multiple Sclerosis?
May 23rd 2025Recognition of the central vein sign with a six-minute MRI demonstrated comparable sensitivity for multiple sclerosis (MS) detection in comparison to oligoclonal band (OCB) assessment, which requires lumbar puncture, according to newly published research.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
